1 – 28 of 28
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Exploring the interplay between antiretroviral therapy and the gut-oral microbiome axis in people living with HIV
(
- Contribution to journal › Article
- 2023
-
Mark
The molecular epidemiology of HIV-1 in Sweden 1996 to 2022, and the influence of migration from Ukraine
2023) In Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 28(48).(
- Contribution to journal › Article
-
Mark
Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort
2023) In Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 76(1).(
- Contribution to journal › Article
-
Mark
Cohort profile: InfCareHIV, a prospective registry-based cohort study of people with diagnosed HIV in Sweden
(
- Contribution to journal › Article
-
Mark
Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV
(
- Contribution to journal › Article
- 2020
-
Mark
HIV AND AGEING: PRIMARY AND SECONDARY PREVENTION OF CAD AMONG PLHIV
(
- Contribution to conference › Abstract
-
Mark
Low-Level Viremia during ART and the Risk of Death, AIDS, and Serious Non-AIDS-events
(
- Contribution to conference › Abstract
-
Mark
All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study
2020) In Clinical Infectious Diseases(
- Contribution to journal › Article
-
Mark
Antiretroviral treatment for HIV infection : Swedish recommendations 2019
(
- Contribution to journal › Scientific review
- 2019
-
Mark
A retrospective analysis of the EuResist data set assessing HIV dual therapy success in a real-life context
2019) 17th European AIDS Conference(
- Contribution to conference › Abstract
- 2018
-
Mark
Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations
(
- Contribution to journal › Article
-
Mark
Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden
(
- Contribution to journal › Article
-
Mark
Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease
(
- Contribution to journal › Article
- 2017
-
Mark
Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients
(
- Contribution to journal › Article
- 2016
-
Mark
Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels
(
- Contribution to journal › Article
- 2015
-
Mark
Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.
(
- Contribution to journal › Article
- 2014
-
Mark
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013
(
- Contribution to journal › Scientific review
-
Mark
T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection.
(
- Contribution to journal › Article
-
Mark
Risk of HIV transmission from patients on antiretroviral therapy: A position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naive HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial
(
- Contribution to journal › Article
- 2011
-
Mark
Bilirubin-A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy
(
- Contribution to journal › Article
-
Mark
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2010
(
- Contribution to journal › Scientific review
- 2010
-
Mark
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-na
- Contribution to journal › Article
-
Mark
Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Naive HIV-1-Infected Patients
(
- Contribution to journal › Article
- 2009
-
Mark
Treatment of HIV infection: Swedish recommendations 2009
(
- Contribution to journal › Scientific review
- 2008
-
Mark
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2007
(
- Contribution to journal › Scientific review
-
Mark
Treatment of chronic hepatitis B infection: An update of Swedish recommendations
(
- Contribution to journal › Scientific review
- 1999
-
Mark
Long-term pattern of HIV-1 RNA load in perinatally infected children
(
- Contribution to journal › Article